Page last updated: 2024-08-22

palladium and finasteride

palladium has been researched along with finasteride in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cahlon, O; Cesaretti, JA; Kollmeier, MA; Stock, RG; Stone, NN	1
Bissonette, E; Miller, N; Smolkin, ME; Theodorescu, D	1

Trials

1 trial(s) available for palladium and finasteride

Article	Year
Combined modality treatment in the management of high-risk prostate cancer. International journal of radiation oncology, biology, physics, 2004, Aug-01, Volume: 59, Issue:5 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy, Conformal; Testosterone	2004

Article

Year

Combined modality treatment in the management of high-risk prostate cancer.

International journal of radiation oncology, biology, physics, 2004, Aug-01, Volume: 59, Issue:5

Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy, Conformal; Testosterone

2004

Other Studies

1 other study(ies) available for palladium and finasteride

Article	Year
Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Cancer, 2005, Jun-15, Volume: 103, Issue:12 Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Humans; Leuprolide; Male; Neoadjuvant Therapy; Neoplasm Staging; Palladium; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Risk Factors; Survival Rate; Testosterone; Treatment Outcome; Ultrasonography, Interventional	2005

Article

Year

Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.

Cancer, 2005, Jun-15, Volume: 103, Issue:12

Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Humans; Leuprolide; Male; Neoadjuvant Therapy; Neoplasm Staging; Palladium; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Risk Factors; Survival Rate; Testosterone; Treatment Outcome; Ultrasonography, Interventional

2005